Article
Cell Biology
Marta M. Morawska, Carlos G. Moreira, Varun R. Ginde, Philipp O. Valko, Tobias Weiss, Fabian Buechele, Lukas L. Imbach, Sophie Masneuf, Sedef Kollarik, Natalia Prymaczok, Juan A. Gerez, Roland Riek, Christian R. Baumann, Daniela Noain
Summary: Enhancing slow-wave sleep in murine models of Parkinson's disease reduces pathological alpha-synuclein accumulation and may improve disease progression through mechanisms such as promoting glymphatic clearance.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Nagendran Ramalingam, Lisa Brontesi, Shan-Xue Jin, Dennis J. Selkoe, Ulf Dettmer
Summary: Research shows that Parkinson's disease-linked mutations in alpha-synuclein can impact the phosphorylation of serine-129, which is important for synaptic transmission. These mutations reduce the levels of phosphorylation and impair its reversibility. Additionally, inhibiting the proteasome also reduces the reversibility of this phosphorylation.
Article
Cell Biology
Lea Elsholz, Yasmine Wasser, Patrick Ziegler, Pardes Habib, Aaron Voigt
Summary: Inhibiting CK1 kinase activity by overexpressing CK1 binding protein (CK1BP) can reduce S129 phosphorylation, oligomerization, and insoluble accumulation of alpha-Syn. The results suggest that CK1BP may have beneficial effects on neurodegenerative diseases and represents a promising target for therapeutic approaches against alpha-synucleinopathies.
Article
Biochemistry & Molecular Biology
Arina Yazawa, Kenneth Hensley, Toshio Ohshima
Summary: This study suggests that phosphorylation of CRMP2 in the hippocampus is related to pathology and memory impairment in DLB, and the experimental therapeutic LKE may have clinical implications in the treatment of alpha-synucleinopathy.
NEUROCHEMICAL RESEARCH
(2022)
Article
Neurosciences
Kathryn M. Miller, Joseph R. Patterson, Joseph Kochmanski, Christopher J. Kemp, Anna C. Stoll, Christopher U. Onyekpe, Allyson Cole-Strauss, Kathy Steece-Collier, Jacob W. Howe, Kelvin C. Luk, Caryl E. Sortwell
Summary: Preclinical studies suggest a potential link between STN DBS and neuroprotection of nigrostriatal dopamine neurons through BDNF signaling, but the impact on alpha-synuclein aggregation and neuroinflammation remains unclear. The study in male rats using the PFF model showed that STN DBS did not affect PFF-induced accumulation of pSyn inclusions in the SNpc, but it did lead to increased BDNF protein in the striatum. These results indicate the potential of STN DBS in modifying the long-term consequences of synucleinopathy.
JOURNAL OF NEUROSCIENCE
(2021)
Article
Virology
Jung-Youn Han, Chaewon Shin, Young Pyo Choi
Summary: The study found that pathological alpha-synuclein aggregates with seeding activity were detectable in the colon of transgenic mice as early as 3 months old, before any neurological abnormalities were observed. In contrast, alpha-syn seeding activity in the brain was only identified in one of three mice at 6 months old. By the symptomatic stage of 12 months, seeding activity was consistently detectable in both the brain and colon.
Article
Biochemistry & Molecular Biology
Jerome Lamontagne-Proulx, Katherine Coulombe, Marc Morissette, Marie Rieux, Frederic Calon, Therese Di Paolo, Denis Soulet
Summary: The mutation and overexpression of alpha-synuclein protein is associated with Parkinson's disease. The prevalence of PD is higher in men than in women, suggesting the involvement of female hormones in slowing PD progression. In mice, male individuals are more vulnerable to toxins and exhibit more severe toxicity from alpha-synuclein protein than females.
Article
Neurosciences
Sheila M. Fleming, Ashley Davis, Emily Simons
Summary: Parkinson's disease is characterized by the abnormal accumulation of alpha-synuclein in the brain and the loss of dopaminergic neurons. Immunotherapies targeting alpha-synuclein have become a key focus for the development of novel therapies for PD.
Article
Biochemistry & Molecular Biology
Winston T. Chu, Jesse Hall, Anjela Gurrala, Alexander Becsey, Shreya Raman, Michael S. Okun, Catherine T. Flores, Benoit I. Giasson, David E. Vaillancourt, Vinata Vedam-Mai
Summary: This study reports on the development of adoptive cellular therapy (ACT) targeted against alpha-synucleinopathies (SPs) and demonstrates its effectiveness in a preclinical SP model. The adoptive transfer of pre-activated T-cells generated from immunized mice improves survival, behavior, brain microstructural impairment, and reduces alpha-synuclein pathology burden. This study provides evidence for ACT as a candidate immunotherapy for other forms of SPs.
ACS CHEMICAL NEUROSCIENCE
(2023)
Article
Clinical Neurology
Avika Chopra, Tiago Fleming Outeiro
Summary: This article discusses the aggregation of alpha-synuclein in Parkinson's disease and the possible sources of disease-related species released in extracellular vesicles, which promises to revolutionize the diagnosis and monitoring of the disease.
Article
Clinical Neurology
Shady Rahayel, Ying-Qiu Zheng, Zhen-Qi Liu, Alaa Abdelgawad, Nooshin Abbasi, Anna Caputo, Bin Zhang, Angela Lo, Victoria Kehm, Michael Kozak, Han Soo Yoo, Alain Dagher, Kelvin C. Luk
Summary: The study investigates the long-term spatiotemporal distribution of Lewy-related pathology in mice injected with alpha-synuclein preformed fibrils and recreates these patterns using a computational model. The findings suggest that both regional connectivity and Snca gene expression play a significant role in the propagation of pathologic alpha-synuclein.
Article
Clinical Neurology
Weijin Liu, Qidi Zhang, Hao Xing, Ge Gao, Jia Liu, Yue Huang, Hui Yang
Summary: A specific p-alpha-syn detection tool has been developed in this study, which can play a role in studying the pathophysiological mechanisms of alpha-synuclein and has significant implications.
FRONTIERS IN NEUROLOGY
(2022)
Article
Medicine, Research & Experimental
Christopher H. Gibbons, Roy Freeman, Bailey Bellaire, Charles H. Adler, Dan Moore, Todd Levine
Summary: Finding a accessible and reliable tool for diagnosing synucleinopathies is an urgent priority. Skin biopsy has the potential to be the clinical test of choice with its high sensitivity and specificity, as well as its suitability for large-scale analysis.
BIOMARKERS IN MEDICINE
(2022)
Article
Clinical Neurology
John Stephen Middleton, Hanna Lynn Hovren, Nelson Kha, Manuel Joseph Medina, Karen Ruth MacLeod, Luis Concha-Marambio, Kendal Jay Jensen
Summary: Parkinson's disease (PD) can be misdiagnosed due to its clinical overlap with atypical parkinsonism. The a-Synuclein (aSyn) Seed Amplification Assay (SAA) has been reported as a potential diagnostic indicator for PD, but its use as a clinical laboratory test has not been validated. This study compares the accuracy of PD clinical diagnosis using the aSyn-SAA test with two different diagnostic inclusion criteria, showing a significant improvement when combined with confirmatory imaging.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Teresa Torre-Muruzabal, Anke van der Perren, Audrey Coens, Geraldine Gelders, Anna Barber Janer, Sara Camacho-Garcia, Therese Klingstedt, Peter Nilsson, Nadia Stefanova, Ronald Melki, Veerle Baekelandt, Wouter Peelaerts
Summary: This study found that the progression of multiple system atrophy is influenced by different types of alpha Syn strains. Alpha Syn strains impact disease progression through oligodendroglial, neurotoxic, and immune-related mechanisms, leading to neurodegeneration and brain atrophy. The activation of microglial cells is associated with the structural features of alpha Syn strains.